Complement gene single nucleotide polymorphisms and biomarker endophenotypes of alzheimer's disease

Journal of Alzheimer's Disease

Volumn 35, Issue 1, 2013, Pages 51-57

  Daborg, Jonny ^a   Holmgren, Sandra ^a   Abramsson, Alexandra ^a   Andreasson, Ulf ^a   Zetterberg, Madeleine ^a   Nilsson, Staffan ^b   Minthon, Lennart ^c   Skoog, Ingmar ^a   Blennow, Kaj ^a   Pekna, Marcela ^a   Hanse, Eric ^a   Zetterberg, Henrik ^a,d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; complement; microglia; single nucleotide polymorphisms

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; BIOLOGICAL MARKER; COMPLEMENT;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COMPLEMENT SYSTEM; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; ENDOPHENOTYPE; FEMALE; GENE LOCATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROCHEMISTRY; NEUROPATHOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84876383039     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-121930     Document Type: Article

References (46)

1. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403. (Pubitemid 44108123)
2. Bertram L, Lill CM, Tanzi RE (2010) The genetics of Alzheimer disease: Back to the future. Neuron 68, 270-281.
3. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A, Pedersen NL (2006) Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 63, 168-174. (Pubitemid 43213878)
4. Scheff SW, Price DA (2003) Synaptic pathology in Alzheimer's disease: A review of ultrastructural studies. Neurobiol Aging 24, 1029-1046. (Pubitemid 37487881)
5. Schafer DP, Stevens B (2010) Synapse elimination during development and disease: Immune molecules take centre stage. Biochem Soc Trans 38, 476-481.
6. Stephan AH, Barres BA, Stevens B (2012) The complement system: An unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci 35, 369-389.
7. Eikelenboom P, Hack CE, Rozemuller JM, Stam FC (1989) Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch B Cell Pathol Incl Mol Pathol 56, 259-262. (Pubitemid 19049180)
8. McGeer PL, Akiyama H, Itagaki S, McGeer EG (1989) Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett 107, 341-346. (Pubitemid 20013261)
9. Yamada T, Akiyama H, McGeer PL (1990) Complementactivated oligodendroglia: A new pathogenic entity identified by immunostaining with antibodies to human complement proteins C3d and C4d. Neurosci Lett 112, 161-166. (Pubitemid 20141697)
10. Haga S, Ikeda K, Sato M, Ishii T (1993) Synthetic Alzheimer amyloid beta/A4 peptides enhance production of complement C3 component by cultured microglial cells. Brain Res 601, 88-94. (Pubitemid 23047669)
11. Eikelenboom P, Veerhuis R (1996) The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol Aging 17, 673-680. (Pubitemid 26348867)
12. Yasojima K, Schwab C, McGeer EG, McGeer PL (1999) Upregulated production and activation of the complement system in Alzheimer's disease brain. Am J Pathol 154, 927-936. (Pubitemid 29122612)
13. Wang Y, Hancock AM, Bradner J, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Edwards KL, Snapinn KW, Goldstein DS, Shi M, Zhang J (2011) Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol 178, 1509-1516.
14. Daborg J, Andreasson U, Pekna M, Lautner R, Hanse E, Minthon L, Blennow K, Hansson O, Zetterberg H (2012) Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease. J Neural Transm 119, 789-797.
15. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K,Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J,Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van BroeckhovenC,Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N,Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41, 1088-1093.
16. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I,Van BroeckhovenC, Alperovitch A, Lathrop M, Amouyel P (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41, 1094-1099.
17. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva E, St George-Hyslop P, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA,Williamson J,Woltjer RL, Cantwell LB, Dombroski BA, Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 43, 436-441.
18. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV, Carassquillo MM, Lambert JC, Harold D, Schrijvers EM, Ramirez-Lorca R, Debette S, LongstrethWTJr, JanssensAC, Pankratz VS, Dartigues JF, Hollingworth P, Aspelund T, Hernandez I, Beiser A, Kuller LH, Koudstaal PJ, Dickson DW, Tzourio C, Abraham R, Antunez C, Du Y, Rotter JI, Aulchenko YS, Harris TB, Petersen RC, Berr C, Owen MJ, Lopez-Arrieta J, Varadarajan BN, Becker JT, Rivadeneira F, Nalls MA, Graff-Radford NR, Campion D, Auerbach S, Rice K, Hofman A, Jonsson PV, Schmidt H, Lathrop M, Mosley TH, Au R, Psaty BM, Uitterlinden AG, Farrer LA, Lumley T, Ruiz A, Williams J, Amouyel P, Younkin SG, Wolf PA, Launer LJ, Lopez OL, van Duijn CM, Breteler MM (2010) Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303, 1832-1840.
19. Ferrari R, Moreno JH, Minhajuddin AT, O'Bryant SE, Reisch JS, Barber RC, Momeni P (2012) Implication of common and disease specific variants in CLU, CR1, and PICALM. Neurobiol Aging 33, 1846 e1847-e1818.
20. Crehan H, Hardy J, Pocock J (2012) Microglia, Alzheimer's disease, and complement. Int J Alzheimers Dis 2012, 983640.
21. Singleton AB, Hardy J, Traynor BJ, Houlden H (2010) Towards a complete resolution of the genetic architecture of disease. Trends Genet 26, 438-442.
22. Zetterberg M, Landgren S, Andersson ME, Palmer MS, Gustafson DR, Skoog I, Minthon L, Thelle DS, Wallin A, Bogdanovic N, Andreasen N, Blennow K, Zetterberg H (2008) Association of complement factor H Y402H gene polymorphism with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 147B, 720-726.
23. Hamilton G, Proitsi P, Williams J, O'Donovan M, Owen M, Powell J, Lovestone S (2007) Complement factor H Y402H polymorphism is not associated with late-onset Alzheimer's disease. Neuromolecular Med 9, 331-334. (Pubitemid 350242636)
24. Le Fur I, Laumet G, Richard F, Fievet N, Berr C, Rouaud O, Delcourt C, Amouyel P, Lambert JC (2010) Association study of the CFH Y402H polymorphism with Alzheimer's disease. Neurobiol Aging 31, 165-166.
25. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J (2012) TREM2 variants in Alzheimer's disease. N Engl J Med. doi: 10.1056/NEJMoa1211851
26. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K (2012) Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. doi: 10.1056/NEJMoa1211103.
27. Kaarniranta K, Salminen A, Haapasalo A, Soininen H, Hiltunen M (2011) Age-related macular degeneration (AMD): Alzheimer's disease in the eye? J Alzheimers Dis 24, 615-631.
28. Kirby E, BandelowS, Hogervorst E (2010)Visual impairment in Alzheimer's disease:Acritical review. J Alzheimers Dis 21, 15-34.
29. Sun C, Zhao M, Li X (2012) CFB/C2 gene polymorphisms and risk of age-related macular degeneration: A systematic review and meta-analysis. Curr Eye Res 37, 259-271.
30. Maller JB, Fagerness JA, Reynolds RC, Neale BM, Daly MJ, Seddon JM (2007)Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet 39, 1200-1201. (Pubitemid 47482689)
31. Yates JR, Sepp T, Matharu BK, Khan JC, ThurlbyDA, Shahid H, Clayton DG, Hayward C, Morgan J,WrightAF, Armbrecht AM, Dhillon B, Deary IJ, Redmond E, Bird AC, Moore AT (2007) Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 357, 553-561. (Pubitemid 47236280)
32. Park KH, Fridley BL, Ryu E, Tosakulwong N, Edwards AO (2009) Complement component 3 (C3) haplotypes and risk of advanced age-related macular degeneration. Invest Ophthalmol Vis Sci 50, 3386-3393.
33. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944. (Pubitemid 14076461)
34. Mirra SS, Heyman A,McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486.
35. Hansson O, ZetterbergH, Buchhave P, Londos E, BlennowK, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5, 228-234. (Pubitemid 43238346)
36. Zetterberg H,Wahlund LO, Blennow K (2003) Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett 352, 67-69. (Pubitemid 37412328)
37. Lewczuk P, Zimmermann R, Wiltfang J, Kornhuber J (2009) Neurochemical dementia diagnostics: A simple algorithm for interpretation of the CSF biomarkers. J Neural Transm 116, 1163-1167.
38. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26, 231-245. (Pubitemid 26002016)
39. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E (2000) Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 7, 245-258.
40. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
41. Livak KJ (1999) Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 14, 143-149. (Pubitemid 29095371)
42. Hu X, Pickering E, Liu YC, Hall S, Fournier H, Katz E, Dechairo B, John S, Van Eerdewegh P, Soares H (2011) Meta-analysis for genome-wide association study identifies multiple variants at the BIN1 locus associated with late-onset Alzheimer's disease. PLoS ONE 6, e16616.
43. Samgard K, Zetterberg H, Blennow K, Hansson O, Minthon L, Londos E (2010) Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. Int J Geriatr Psychiatry 25, 403-410.
44. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O (2010) CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 74, 1531-1537.
45. van Rossum IA, Vos SJ, Burns L, Knol DL, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, L'Italien G, van der Flier WM, Teunissen CE, Blennow K, Barkhof F, Rueckert D, Wolz R, Verhey F, Visser PJ (2012) Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology 79, 1809-1816.
46. Mungas D (1991) In-office mental status testing: A practical guide. Geriatrics 46, 54-58, 63, 66f.